Comparing hematology analyzers for procurement requires separating documented analytical performance from vendor claims and feature lists. A 2026 comparative evaluation of four five-part differential instruments—Siemens Advia 2120i, Sysmex XN-1000, Mindray BC-5310 CRP and Beckman Coulter DxH 900—shows that instruments can meet most acceptance criteria while still differing in repeatability, accuracy and limits of quantification [1]. Procurement teams should therefore structure the comparison around a verification protocol: precision, accuracy, linearity, limits of blank, detection and quantification, and carryover [1]. The Clinical and Laboratory Standards Institute document H26-A2 provides the framework for validation, verification, calibration and quality assurance of automated multichannel hematology analyzers [2]. This article explains the named workflow, the technical decision points, the evidence limitations and a concrete evaluation example without turning the process into generic buying advice.

Start with the verification protocol, not the brochure

The first decision point is whether the laboratory needs validation or verification. According to ISO 15189, a laboratory should implement analyzers that are validated for the intended purpose, with validation performed by the manufacturer and verification by the clinical laboratory of the manufacturer's claims [6]. CLSI H26-A2 expands this distinction with guidance for validation, verification, calibration, quality assurance and quality control of automated multichannel hematology analyzers [2]. A procurement comparison should therefore request the manufacturer's validation data and plan an independent verification of the shortlisted instruments.

The verification protocol in the 2026 four-analyzer study assessed precision, accuracy, linearity, limits of blank, detection and quantification, and carryover, with acceptance criteria following manufacturer specifications and biological variability analytical performance specifications [1]. The Advia 2120i served as the reference analyzer for accuracy assessment [1]. This structure gives procurement teams a reproducible checklist. Without it, comparisons default to throughput and reagent counts, which do not reveal whether an instrument can reliably quantify low leukocyte or platelet concentrations in the patient populations the laboratory actually serves.

Read the low-end performance data closely

Similar broad acceptability can hide meaningful differences at clinically important low concentrations. In the 2026 evaluation, all analyzers showed acceptable precision for most CBC parameters, but the XN-1000 and DxH 900 showed the best repeatability [1]. The Mindray BC-5310 CRP had the highest proportion of parameters exceeding acceptance criteria: low leukocytes in control at 2.9 percent, and low platelets at 6.1 percent as well as low leukocytes at 16.4 percent and high leukocytes at 4.1 percent in patient samples [1]. The Advia 2120i showed suboptimal repeatability at low hemoglobin in control, with a CV of 1.1 percent at 53 g/L, and low leukocytes at 4.7 percent for patient samples [1].

Limits of quantification also separated the instruments. Determined LoQ for leukocytes were 0.1 × 10⁹/L for the Advia 2120i and 0.3 × 10⁹/L for the XN-1000, BC-5310 CRP and DxH 900 [1]. For platelets, LoQ values were 3 × 10⁹/L for Advia 2120i, 4 for XN-1000, 5 for DxH 900 and 10 for BC-5310 CRP [1]. Platelet repeatability varied most, with CVs from 5.4 percent to 9.7 percent [1]. A laboratory managing oncology or hematology patients with frequent low counts should weight these findings more heavily than a laboratory whose routine workload rarely approaches those thresholds.

Questions to put to each vendor before shortlisting

Request the manufacturer's validation report and the specific acceptance criteria used for precision, accuracy, linearity, LoB, LoD, LoQ and carryover [1]. Ask for the instrument's determined LoQ for leukocytes and platelets, not just the claimed analytical range [1]. Confirm whether the analyzer provides a three-part or five-part differential and whether flow cytometry-based parameters such as reticulocyte count are available [8]. Ask how many reagents are required for the parameters the laboratory needs, how many tests can be run before reagent replacement, whether reagents can be purchased from any supplier or only the manufacturer, whether non-toxic reagents can be used, and what waste disposal requirements apply [8]. For low-volume or point-of-care settings, confirm sample volume and CLIA status, as with the XW-100's approximately 15 μL venous sample and CLIA-waived designation [7].

Use external quality assessment data as a second lens

Single-site verification studies have limits, so procurement teams can add external quality assessment data. A 2026 analysis of National Center for Clinical Laboratories EQA data from 2020 to 2024 grouped Sysmex and Mindray blood cell analysis systems into six categories based on instrument models, detection methods or reagent properties [3]. The authors calculated Z-scores and total allowable error for WBC, RBC and platelet counting, then compared laboratory TEa with minimum, desirable and optimal tiers of biological variation-based TEa [3].

The results were parameter-specific. For RBC, the Sysmex group designated as Sysmex (3) achieved the optimal standard, while the Mindray (2) group met only the minimum standard and the other groups met the desirable standard [3]. For platelets, only the Sysmex (3) and Mindray (3) groups reached the minimum standard; the other peer groups did not meet the minimum standard [3]. This does not identify a universal winner. It shows that peer-group performance can differ by parameter and by instrument configuration, so procurement teams should request EQA performance data for the exact model and reagent system under consideration rather than relying on brand reputation.

Match throughput, sample volume and differential type to the setting

Analytical performance must be weighed against operational fit. Beckman Coulter lists the DxH 900 at up to 100 samples per hour, the DxH 690T at up to 100 samples per hour, and the DxH 500 at up to 60 samples per hour with a 12 μL blood requirement [5]. The Sysmex XW-100 is a CLIA-waived CBC analyzer that provides results in three minutes from approximately 15 μL of venous blood and offers 12 parameters including a three-part differential [7]. These are different instruments for different settings, and the comparison should not treat them as interchangeable.

The differential type is a structural decision point. Labcompare notes that analyzers using only impedance measurements can differentiate three size categories, while five-part differentials—neutrophils, basophils, monocytes, eosinophils and lymphocytes—are enabled through flow cytometry [8]. A three-part analyzer may be appropriate for a low-volume office laboratory, while a five-part instrument with reticulocyte capability may be required for a hospital core laboratory. The CAP TODAY product guide provides additional operational fields, including dimensions, country of design and manufacture, first year sold in the U.S., approximate installed units, onboard diagnostics and remote access [4]. These fields support logistics and service planning but do not substitute for verification data.

A concrete evaluation example for a mid-volume hospital laboratory

Consider a suggested hypothetical workflow for a 400-bed hospital laboratory evaluating the XN-1000, DxH 900 and BC-5310 CRP. The laboratory would first confirm that each instrument provides a five-part differential and meets the required throughput. It would then request manufacturer validation data and design a verification plan following CLSI H26-A2, including within-run and between-batch precision using stabilized quality control samples over a 20-day period [6]. The 2016 review notes that between-batch precision is affected by random error and drift, and that manufacturers' claims about both within-run and between-batch precision must be verified [6].

The laboratory would then test low-end performance using patient samples with low leukocyte and platelet counts. Based on the 2026 study, the XN-1000 and DxH 900 showed the best repeatability, while the BC-5310 CRP had the highest proportion of parameters exceeding acceptance criteria in patient samples [1]. Platelet accuracy was significantly different on the XN-1000, with p = 0.04, and on the BC-5310 CRP, with p = 0.05 [1]. The laboratory would also review EQA data for its specific peer group. This example is a suggestion, not a tested procurement outcome, and the final choice would depend on local patient mix, service support and reagent logistics.